T cell leukemia homeobox (TLX) Inhibitors
T cell leukemia homeobox (TLX) signaling is a critical regulatory pathway predominantly studied in the context of neural development and brain function. TLX, a member of the nuclear receptor family of transcription factors, plays a pivotal role in regulating the balance between neural stem cell proliferation and differentiation. In the brain, TLX is known to maintain neural stem cells in an undifferentiated and proliferative state, influencing neurogenesis during development and in the adult brain. It achieves this by regulating the expression of target genes involved in cell cycle control, apoptosis, and stem cell maintenance.
T cell leukemia homeobox (TLX) aim to modulate these processes by interfering with the ability of TLX to bind DNA or by influencing its interaction with co-regulatory proteins. The development of TLX inhibitors is driven by the need to understand the molecular mechanisms underlying neural development and the potential dysregulation of these pathways. This class of inhibitors targets the functional domains of TLX, especially the DNA-binding domain or the ligand-binding domain, to its interaction with target genes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Inhibits class I and II HDAC and may disrupt T cell leukemia homeobox (TLX) signaling s. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A potent and non-selective HDAC inhibitor, often used in research and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Approved for cutaneous T cell lymphoma, it selectively inhibits class I HDACs and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
A pan-HDAC inhibitor with broad-spectrum activity and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Similar to 5-azacytidine, it's used for myelodysplastic syndromes and acute myeloid leukemia and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
A cytidine analog with DNA methyltransferase inhibitory activity, mainly used in research and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, primarily used as an immunosuppressant and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another potent inhibitor of PI3K, used for experimental purposes and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
An mTOR inhibitor may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
A pan-PI3K inhibitor, investigated in research models for cancer therapy and may disrupt T cell leukemia homeobox (TLX) signaling . | ||||||